Prostaglandin E2 Inhibits p53 in Human Breast Adipose Stromal Cells: A Novel Mechanism for the Regulation of Aromatase in Obesity and Breast Cancerl

被引:42
|
作者
Wang, Xuyi [1 ,2 ]
Docanto, Maria M. [1 ]
Sasano, Hironobu [3 ]
Lo, Camden
Simpson, Evan R. [1 ,5 ]
Brown, Kristy A. [1 ,2 ,6 ]
机构
[1] MIMR PHI Inst Med Res, Ctr Canc Res, Metab & Canc Lab, Clayton, Vic 3168, Australia
[2] Monash Univ, Dept Physiol, Clayton, Vic, Australia
[3] Tohoku Univ, Sch Med, Dept Pathol, Sendai, Miyagi 980, Japan
[4] Univ Melbourne, Sir Peter MacCallum Canc Ctr, Dept Oncol, Melbourne, Vic, Australia
[5] Monash Univ, Clayton, Vic, Australia
[6] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
P450; CYP19; GENE; TUMOR-SUPPRESSOR; CYCLIC-AMP; TRANSCRIPTIONAL REPRESSION; PROXIMAL PROMOTER; MAMMARY-GLAND; EXPRESSION; INFLAMMATION; TISSUE; RECEPTOR;
D O I
10.1158/0008-5472.CAN-14-2164
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Obesity is a risk factor for postmenopausal breast cancer and the majority of these cancers are estrogen dependent. Aromatase converts androgens into estrogens and its increased expression in breast adipose stromal cells (ASC) is a major driver of estrogen receptor-positive breast cancer. In particular, obesity-associated and tumor-derived factors, such as prostaglandin E-2 (PGE(2)), have been shown to drive the expression of aromatase by stimulating the activity of the proximal promoter II (PII). The tumor-suppressor p53 is a key regulator of cell-cycle arrest and apoptosis and is frequently mutated in breast cancer. Mutations in p53 are rare in tumor-associated ASCs. Therefore, it was hypothesized that p53 is regulated by PGE(2) and involved in the PGE(2)-mediated regulation of aromatase. Results demonstrate that PGE(2) causes a significant decrease in p53 transcript and nuclear protein expression, as well as phosphorylation at Ser15 in primary human breast ASCs. Stabilization of p53 with RITA leads to a significant decrease in the PGE(2)-stimulated aromatase mRNA expression and activity, and PII activity. Interaction of p53 with PII was demonstrated and this interaction is decreased in the presence of PGE(2). Moreover, mutation of the identified p53 response element leads to an increase in the basal activity of the promoter. Immunofluorescence on clinical samples demonstrates that p53 is decreased in tumor-associated ASCs compared with ASCs from normal breast tissue, and that there is a positive association between perinuclear (inactive) p53 and aromatase expression in these cells. Furthermore, aromatase expression is increased in breast ASCs from Li-Fraumeni patients (germline TP53 mutations) compared with non-Li-Fraumeni breast tissue. Overall, our results demonstrate that p53 is a negative regulator of aromatase in the breast and its inhibition by PGE(2) provides a novel mechanism for aromatase regulation in obesity and breast cancer. (C)2015 AACR.
引用
收藏
页码:645 / 655
页数:11
相关论文
共 50 条
  • [31] Violacein induces apoptosis in human breast cancer cells through up regulation of BAX, p53 and down regulation of MDM2
    Alshatwi, Ali A.
    Subash-Babu, P.
    Antonisamy, P.
    EXPERIMENTAL AND TOXICOLOGIC PATHOLOGY, 2016, 68 (01) : 89 - 97
  • [32] Prostaglandin E2 stimulates p53 transactivational activity through specific serine 15 phosphorylation in human synovial fibroblasts
    Faour, Wissam H.
    He, QingWen
    Mancini, Arturo
    Jovanovic, Dragan
    Antoniou, John
    Di Battista, John A.
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (29) : 19849 - 19860
  • [33] Progesterone inhibits growth and induces apoptosis in breast cancer cells: Inverse on bcl-2 and p53
    Formby, B
    Wiley, TS
    ANNALS OF CLINICAL AND LABORATORY SCIENCE, 1998, 28 (06): : 360 - 369
  • [34] Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity
    Xu, M
    Kumar, D
    Srinivas, S
    Detolla, LJ
    Yu, SF
    Stass, SA
    Mixson, AJ
    HUMAN GENE THERAPY, 1997, 8 (02) : 177 - 185
  • [35] Prostaglandin E2 induces breast cancer-related aromatase promoters via activation of p38 and c-jun NH2-Terminal kinase in adipose fibroblasts
    Chen, Dong
    Reierstad, Scott
    Lin, Zhihong
    Lu, Meiling
    Brooks, Chris
    Li, Newton
    Innes, Jon
    Bulun, Serdar E.
    CANCER RESEARCH, 2007, 67 (18) : 8914 - 8922
  • [36] AP-2α and AP-2γ are transcriptional targets of p53 in human breast carcinoma cells
    Li, H.
    Watts, G. S.
    Oshiro, M. M.
    Futscher, B. W.
    Domann, F. E.
    ONCOGENE, 2006, 25 (39) : 5405 - 5415
  • [37] AP-2α and AP-2γ are transcriptional targets of p53 in human breast carcinoma cells
    H Li
    G S Watts
    M M Oshiro
    B W Futscher
    F E Domann
    Oncogene, 2006, 25 : 5405 - 5415
  • [38] Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells
    Ghosh, Sagar
    Lu, Yunzhe
    Katz, Adam
    Hu, Yanfen
    Li, Rong
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2007, 292 (01): : E246 - E252
  • [39] COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
    Synnott, Naoise C.
    O'Connell, David
    Crown, John
    Duffy, Michael J.
    BREAST CANCER RESEARCH AND TREATMENT, 2020, 179 (01) : 47 - 56
  • [40] COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
    Naoise C. Synnott
    David O’Connell
    John Crown
    Michael J. Duffy
    Breast Cancer Research and Treatment, 2020, 179 : 47 - 56